Faron Pharmaceuticals Oy ("Faron"), the clinical stage biopharmaceutical company, announces today its intention to raise new funds through a placing and offer for subscription (the "Placing and Subscription") and to apply for admission of its ordinary shares to trading on the AIM market of the London Stock Exchange ("Admission").
